Bowen Liu, PhD, investing partner, and Surya Ganguli, PhD, venture partner, join Vijay Pande, PhD, general partner of a16z Bio + Health.

Together, they detail different methods through which AI could assist drug development, the opportunity for AI to flag new targets and compounds for scientists to investigate, and the science fiction-sounding notion of developing a foundation model that untangles biology.

This is an in-depth conversation from three AI experts and biologists, so we’ll also publish the transcript alongside the episode on our website if you want to follow along.

 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.